Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder: A Pilot Study
The University of Texas Health Science Center, Houston
Summary
The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS) and completion rate.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Meet Diagnostic and Statistical Manual of Mental Disorders(DSM-5)criteria for primary stimulant use disorder (either cocaine or methamphetamine) * Be fluent in English and able to understand the consent form Exclusion Criteria: * Have an opioid use disorder of any severity * Have a greater than moderate substance use disorder on any other substance * Undergoing medication-assisted treatment for withdrawal of any substance * Have any medical conditions contraindicating SUVO (e.g., severe pulmonary disease, severe cardiovascular disease or clinically abnormal ECG, severe…
Interventions
- DrugSUVO
Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11
- DrugTAU
Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.
Location
- The University of Texas Health Science Center at HoustonHouston, Texas